We are delighted to have advised MAP Patient Access on their sale of a majority stake to Kester Capital.
MAP is a leading provider of market access consulting services to the pharmaceutical and biotech sectors, with expertise in rare and orphan diseases and cell and gene therapies. MAP’s integrated approach blends best-in-class consulting with membership including its proprietary digital platform, MAP Online, which provides market access intelligence to its customers.
Founded by Christian and Dawn Hill in 2012, MAP has supported more than 70% of all highly specialised technology evaluations by the National Institute of Health and Care Excellence (NICE) to date and supported the development of 200+ new health technology assessments and pricing submissions.
The founders sought a strategic investment partner to help deliver the next stage of the company’s growth.
We have been working closely with the shareholders and the leadership team since 2020 to develop a transaction strategy. Kester Capital’s life sciences credentials made it the ideal partner to support MAP’s growth aspiration. Our deal team project managed the transaction process, navigating a number of complex issues to deliver an excellent outcome for the shareholders.
Doug Bentley commented “MAP is a high quality consultancy with deep expertise across orphan and ultra orphan diseases and cell & gene therapies. The strong cultural and strategic alignment with Kester will help the business to deliver its ambitious growth plans.”
